1YAMAMOTO S, HAYAISHI O. Tryptophan pyrrolase of rabbit intestine:D- and L-tryptophan-cleaving enzyme or enzymes [ J ]. J Biol Chem, 1967, 242 (22) :5260 - 5266.
2BIANCHI M, BERTINI R, GHEZZI P. Induction of indoleamine dioxygenase by interferon in mice: a study with different recombinant interferons and various cytoKi nes[J]. Biochem Biophys Res Commun, 1988,152( 1 ) : 237 - 242.
3BODAGHI B, GOUREAU O, ZIPETO D, et al. Role of IFN-γ induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells [ J ]. J Immunol, 1999,162 (2) :957 - 964.
4ROY E J, TAIKAWA O, KRANZ D M, et al. Neuronal localization of indoleamine 2,3-dioxygenase in mice[ J]. Neurosci Lett,2005,387 (2) :95 - 99.
5MUNN D H, SHATIZADEH E, ATTWOOD J T, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism [ J]. J Exp Med, 1999, 189 (9) :1363 - 1372.
6MUNN D H, ZHOU M, ATTWOOD J T, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism [ J ]. Science, 1998,281 ( 5380 ) : 1191 - 1193.
7FRIBERG M,JENNINGS R,ALSARRAAJ M,et al. Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T-cell mediated rejection [ J ]. Int J Cancer,2002,101 (2) : 151 - 155.
8TERNESS P,CHUANG J J,BAUER T,et al. Regulation of human auto- and alloreactive T cells by 2, 3-dioxygenase ( IDO ) -producing dendritic cells : too much ado about IDO [ J ]. Blood, 2005, 105 ( 6 ) : 2480 - 2486.
9KATZ B J, MULLER A J, PRENDERGAST G C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape [ J ]. Immunol Rev, 2008, 222:206 - 221.
10SUGIMOTO H, ODA S, OTSUKI T, et al. Crystal structure of human indoleamine 2, 3-dioxygenase: catalytic mechanism of O2 incorporation by a heme- containing dioxygenase [ J ]. Proc Nail Acad Sci USA,2006,103(8) :2611 - 2616.
3Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocel: lular carcinoma patients induces CIM CD25 Foxp3 T cells [ J ]. Gastroenterology, 2008,135 ( 1 ) :234-243.
4Lesokhin AM, Hohl TM, Kitano S, et al. MonoeyticCCR2 myeloid- derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment [ J]. Cancer Res,2012,72(4) :876-886.
5Yokoyama I, Waxman F. Differential susceptibility of immunecomp- lexs to release from the erythrocyte CR, receptor by factort [J ]. Mol Immunol, 1994,31 (4) :227.
6Chang B, Liu G, Yang G, et al. REDD1 is required tbr RAS. media ted transformation of human ovarian epithelial cells [ J ]. Cell Cycle ,2009,8 (5) :780-786.
7Kottakis F, Polytarchou C, Foltopoulou P, et al. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/ KDM2B-mir-101 -EZH2 pathway [ J ]. Molecular Cell, 2011,43 : 285 -298.
8Sharon EJ, Jonathan B, Chen XQ, et al. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the Ovarian Cancer Association consortium [ J ] Twin Res Hum Genet ,2009,12 ( 3 ) :269-275.
9Pouzo MG, Lesurf R, Petkiewicz S, et al. Met induces mammary tunor8 with diverse histologies and. is associated with poor outcome andhuman basal breast cancer [ J ]. Pmc Natl Acad Sci USA,2009,106(31 ) :12903-12908.
